Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
Fresenius Kabi saw a sales and earnings slump in its North America business in the final quarter of last year, which dragged heavily on the firm’s full-year operations. Management have conceded that one of those factors, manufacturing issues at its Melrose Park facility, will blow into 2021, with no product approvals or launches anticipated from the site.
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.